

ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Advocate 40 mg + 4 mg spot-on solution for small cats and ferrets
Advocate 80 mg + 8 mg spot-on solution for large cats

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Active substances:

Advocate for cats contains 100 mg/ml imidacloprid and 10 mg/ml moxidectin.

Each unit dose (pipette) delivers:

	Unit Dose	Imidacloprid	Moxidectin
Advocate for small cats (≤ 4 kg) and ferrets	0.4 ml	40 mg	4 mg
Advocate for large cats ($> 4-8$ kg)	0.8 ml	80 mg	8 mg

Excipients:

Benzyl alcohol
Butylhydroxytoluene 1 mg/ml (E 321; as antioxidant).

For a full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Spot-on solution.
Clear yellow to brownish solution.

4. CLINICAL PARTICULARS

4.1 Target species

Cats, ferrets

4.2 Indications for use, specifying the target species

For cats suffering from, or at risk from, mixed parasitic infections:

For the treatment and prevention of flea infestation (*Ctenocephalides felis*), treatment of ear mite infestation (*Otodectes cynotis*), prevention of heartworm disease (L3 and L4 larvae of *Dirofilaria immitis*) and treatment of infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of *Toxocara cati* and *Ancylostoma tubaeforme*).

The product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).

For ferrets suffering from, or at risk from, mixed parasitic infections:

For the treatment and prevention of flea infestation (*Ctenocephalides felis*) and the prevention of heartworm disease (L3 and L4 larvae of *Dirofilaria immitis*).

4.3 Contraindications

Do not use in kittens under 9 weeks of age.
Do not use in the case of hypersensitivity to the active substances or to any of the excipients.

For ferrets: Do not use Advocate for large cats (0.8 ml) or Advocate for dogs (any size).

For dogs, the corresponding “Advocate for dog” product, which contains 100 mg/ml imidacloprid and 25 mg/ml moxidectin, must be used.

4.4 Special warnings

Please refer to section 4.5.

The product’s efficacy has not been tested in ferrets weighing over 2 kg and therefore the duration of effect might be shorter in these animals.

Brief contact of the animal with water on one or two occasions between monthly treatments is unlikely to significantly reduce the efficacy of the product. However, frequent shampooing or immersion of the animal in water after treatment may reduce the efficacy of the product.

Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class.

4.5 Special precautions for use

Special precautions for use in animals

The treatment of cats weighing less than 1 kg and ferrets weighing less than 0.8 kg should be based on a risk-benefit assessment.

There is limited experience on the use of the product in sick and debilitated animals, thus the product should only be used based on a risk-benefit assessment for these animals.

Care should be taken that the content of the pipette or the applied dose does not come into contact with the eyes or mouth of the recipient and/or other animals. Do not allow recently treated animals to groom each other. Oral uptake by Collies, Old English Sheepdogs and related breeds or crossbreeds should be prevented.

It is recommended that cats and ferrets living in, or travelling to areas endemic for heartworm are treated monthly with the product to protect them from heartworm disease.

Whilst the accuracy of diagnosis of heartworm infection is limited, it is recommended that attempts be made to check the heartworm status of any cat and ferret aged over 6 months, before beginning prophylactic treatment, as use of the product on cats or ferrets which have adult heartworms may cause serious adverse effects, including death. If adult heartworm infection is diagnosed, the infection should be treated in accordance with current scientific knowledge.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Avoid contact with skin, eyes or mouth.

Do not eat, drink or smoke during application.

Wash hands thoroughly after use.

After application do not stroke or groom animals until the application site is dry.

In case of accidental spillage onto skin, wash off immediately with soap and water.

People with a known hypersensitivity to benzyl alcohol, imidacloprid or moxidectin should administer the product with caution.

In very rare cases the product may cause skin sensitisation or transient skin reactions (for example numbness, irritation or burning/tingling sensation).

In very rare cases the product may cause respiratory irritation in sensitive individuals.

If the product accidentally gets into eyes, they should be thoroughly flushed with water. If skin or eye symptoms persist, or the product is accidentally swallowed, seek medical attention and show the package insert to the physician.

The solvent in Advocate may stain or damage certain materials including leather, fabrics, plastics and finished surfaces. Allow the application site to dry before permitting contact with such materials.

4.6 Adverse reactions (frequency and seriousness)

Use of the product may result in transient pruritus in cats. On rare occasions greasy fur, erythema and vomiting can occur. These signs disappear without further treatment. The product may, in rare cases, cause local hypersensitivity reactions. If the animal licks the application site after treatment, neurological signs (most of which are transient) may be observed in very rare cases (see section 4.10).

The product tastes bitter. Salivation may occasionally occur if the animal licks the application site immediately after treatment. This is not a sign of intoxication and disappears within some minutes without treatment. Correct application will minimise licking of the application site.

The product may in very rare cases cause at the application site a sensation resulting in transient behavioural changes such as lethargy, agitation, and inappetence.

4.7 Use during pregnancy, lactation or lay

The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Laboratory studies with either imidacloprid or moxidectin in rats and rabbits have not produced any evidence of teratogenic, foetotoxic or maternotoxic effects.

Use only according to the risk-benefit assessment by the responsible veterinarian.

4.8 Interaction with other medicinal products and other forms of interaction

During treatment with Advocate no other antiparasitic macrocyclic lactone should be administered.

No interactions between Advocate and routinely used veterinary medicinal products or medical or surgical procedures have been observed.

4.9 Amounts to be administered and administration route

Dosage schedule for cats:

The recommended minimum doses are 10 mg/kg bodyweight imidacloprid and 1.0 mg/kg bodyweight moxidectin, equivalent to 0.1 ml/kg bodyweight Advocate for cats.

The treatment schedule should be based on the local epidemiological situation.

Weight of cat [kg]	Pipette size to be used	Volume [ml]	Imidacloprid [mg/kg bw]	Moxidectin [mg/kg bw]
≤ 4 kg	Advocate for small cats	0.4	minimum of 10	minimum of 1
> 4–8 kg	Advocate for large cats	0.8	10–20	1–2
> 8 kg	the appropriate combination of pipettes			

Flea treatment and prevention

One treatment prevents future flea infestation for 4 weeks. Existing pupae in the environment may emerge for 6 weeks or longer after treatment is initiated, depending upon climatic conditions. Therefore, it may be necessary to combine Advocate treatment with environmental treatments aimed at breaking the flea life cycle in the surroundings. This can result in a more rapid reduction in the

household flea population. The product should be administered at monthly intervals when used as part of a treatment strategy for flea allergy dermatitis.

Treatment of ear mite infestation (*Otodectes cynotis*)

A single dose of the product should be administered. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment. Do not apply directly to the ear canal.

Heartworm prevention

Cats in areas endemic for heartworm, or those which have travelled to endemic areas, may be infected with adult heartworms. Therefore prior to treatment with Advocate, the advice provided in section 4.5 should be considered.

For prevention of heartworm disease, the product must be applied at regular monthly intervals during the time of the year when mosquitoes (the intermediate hosts which carry and transmit heartworm larvae) are present. The product may be administered throughout the year or at least 1 month before the first expected exposure to mosquitoes. Treatment should continue at regular monthly intervals until 1 month after the last exposure to mosquitoes. To establish a treatment routine, it is recommended that the same day or date be used each month. When replacing another heartworm preventative product in a heartworm prevention programme, the first treatment with Advocate must be given within 1 month of the last dose of the former medication.

In non-endemic areas there should be no risk of cats having heartworm. Therefore they can be treated without special precautions.

Roundworm and hookworm treatment

In areas endemic for heartworm, monthly treatment may significantly reduce the risk of re-infection caused by the respective roundworms and hookworms. In areas non-endemic for heartworm, the product can be used as part of a seasonal prevention programme against fleas and gastrointestinal nematodes.

Dosage schedule for ferrets:

One pipette of Advocate spot-on solution for Small Cats (0.4 ml) should be administered per animal. Do not exceed the recommended dose. The treatment schedule should be based on the local epidemiological situation.

Flea treatment and prevention

One treatment prevents future flea infestation for 3 weeks. Under heavy flea pressure it may be necessary to repeat administration after 2 weeks.

Heartworm prevention

Ferrets in areas endemic for heartworm, or those which have travelled to endemic areas, may be infected with adult heartworms. Therefore prior to treatment with Advocate, the advice provided in section 4.5 should be considered.


For prevention of heartworm disease, the product must be applied at regular monthly intervals during the time of the year when mosquitoes (the intermediate hosts which carry and transmit heartworm larvae) are present. The product may be administered throughout the year or at least 1 month before the first expected exposure to mosquitoes. Treatment should continue at regular monthly intervals until 1 month after the last exposure to mosquitoes.

In non-endemic areas there should be no risk of ferrets having heartworm. Therefore they can be treated without special precautions.


Method of administration

For external use only.

Remove one pipette from the package. Then hold the pipette in an upright position, and twist and pull off the cap. Reverse the cap and use it to twist and remove the seal from the pipette, as shown.



Part the fur on the animal's neck at the base of the skull until the skin is visible. Place the tip of the pipette on the skin and squeeze the pipette firmly several times to empty its contents directly onto the skin. Application at the base of the skull will minimise the opportunity for the animal to lick the product. Apply only to undamaged skin.



4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

Up to 10 times the recommended dose was tolerated in cats with no evidence of adverse effects or undesirable clinical signs.

The product was administered to kittens at up to 5 times the recommended dose, every 2 weeks for 6 treatments, and there were no serious safety concerns. Transient mydriasis, salivation, vomiting and transient rapid respiration were observed.

After accidental oral ingestion or overdose, neurological signs (most of which are transient) such as ataxia, generalised tremors, ocular signs (dilated pupils, little pupillary reflex, nystagmus), abnormal respiration, salivation and vomiting may occur in very rare cases.

The product was administered to ferrets at 5 times the recommended dose, every 2 weeks for 4 treatments, and there was no evidence of adverse effects or undesirable clinical signs.

In case of accidental oral uptake, symptomatic treatment should be administered. There is no known specific antidote. The use of activated charcoal may be beneficial.

4.11 Withdrawal period(s)

Not applicable.

5. PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: therapeutic antiparasitic agent; ATCvet code: QP54AB52.

5.1 Pharmacodynamic properties

Imidacloprid, 1-(6-Chloro-3-pyridylmethyl)-N-nitro-imidazolidin-2-ylideneamine is an ectoparasiticide belonging to the chloronicotinyl group of compounds. Chemically, it is more accurately described as a chloronicotinyl nitroguanidine. Imidacloprid is effective against larval flea stages and adult fleas. Flea larvae in the pet's surroundings are killed after contact with a pet treated with the product. Imidacloprid has a high affinity for the nicotinic acetylcholine receptors in the post-synaptic region of the central nervous system (CNS) of the flea. The ensuing inhibition of cholinergic transmission in insects results in paralysis and death. Due to the weak nature of the interaction with mammalian nicotinic receptors and the postulated poor penetration through the blood-brain barrier in mammals, it has virtually no effect on the mammalian CNS. Imidacloprid has minimal pharmacological activity in mammals.

Moxidectin, 23-(O-methyloxime)-F28249 alpha is a second-generation macrocyclic lactone of the milbemycin family. It is a parasiticide which is active against many internal and external parasites. Moxidectin is active against larval stages (L3, L4) of *Dirofilaria immitis*. It is also active against gastrointestinal nematodes. Moxidectin interacts with GABA and glutamate-gated chloride channels. This leads to opening of the chloride channels on the postsynaptic junction, the inflow of chloride ions and induction of an irreversible resting state. The result is flaccid paralysis of affected parasites, followed by their death and/or expulsion.

5.2 Pharmacokinetic particulars

After topical administration of the product, imidacloprid is rapidly distributed over the animal's skin within one day of application. It can be found on the body surface throughout the treatment interval. Moxidectin is absorbed through the skin, reaching maximum plasma concentrations approximately 1 to 2 days after treatment in cats. Following absorption from the skin, moxidectin is distributed systemically and is slowly eliminated from the plasma as manifested by detectable moxidectin concentrations in plasma throughout the treatment interval of one month.

Environmental properties

See section 6.6.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Benzyl alcohol
Butylhydroxytoluene
Propylene carbonate

6.2 Incompatibilities

None known.

6.3 Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale: 3 years.

6.4 Special precautions for storage

Do not store above 30 °C.

6.5 Nature and composition of immediate packaging

Pack sizes 0.4 ml and 0.8 ml per pipette.
Blister pack containing 1, 2, 3, 4, 6, 9, 12, 21 or 42 unit dose pipettes.

Container material White polypropylene unit dose pipette with screw cap.

Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Advocate should not be allowed to enter surface waters as it has harmful effects on aquatic organisms.

7. MARKETING AUTHORISATION HOLDER

Bayer Animal Health GmbH
D-51368 Leverkusen
Germany

8. MARKETING AUTHORISATION NUMBER(S)

EU/2/03/039/001-004, EU/2/03/039/013-014, EU/2/03/039/019-022, EU/2/03/039/031-038

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

04/2003

10. DATE OF REVISION OF THE TEXT

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency <http://www.ema.europa.eu/>.

PROHIBITION OF SALE, SUPPLY AND/OR USE

Not applicable.

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Advocate 40 mg + 10 mg spot-on solution for small dogs
Advocate 100 mg + 25 mg spot-on solution for medium dogs
Advocate 250 mg + 62.5 mg spot-on solution for large dogs
Advocate 400 mg + 100 mg spot-on solution for extra-large dogs

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Active substances:

Advocate for dogs contains 100 mg/ml imidacloprid and 25 mg/ml moxidectin.

Each unit dose (pipette) delivers:

	Unit Dose	Imidacloprid	Moxidectin
Advocate for small dogs (≤ 4 kg)	0.4 ml	40 mg	10 mg
Advocate for medium dogs (> 4 –10 kg)	1.0 ml	100 mg	25 mg
Advocate for large dogs (> 10 –25 kg)	2.5 ml	250 mg	62.5 mg
Advocate for extra-large dogs (> 25 –40 kg)	4.0 ml	400 mg	100 mg

Excipients:

Benzyl alcohol
Butylhydroxytoluene 1 mg/ml (E 321; as antioxidant)

For a full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Spot-on solution.
Clear yellow to brownish solution.

4. CLINICAL PARTICULARS

4.1 Target species

Dogs

4.2 Indications for use, specifying the target species

For dogs suffering from, or at risk from, mixed parasitic infections:

For the treatment and prevention of flea infestation (*Ctenocephalides felis*), treatment of biting lice (*Trichodectes canis*), treatment of ear mite infestation (*Otodectes cynotis*), sarcoptic mange (caused by *Sarcoptes scabiei* var. *canis*), demodicosis (caused by *Demodex canis*), prevention of heartworm disease (L3 and L4 larvae of *Dirofilaria immitis*) and angiostrongylosis (L4 larvae and immature adults of *Angiostrongylus vasorum*), treatment of *Angiostrongylus vasorum* and *Crenosoma vulpis* and treatment of infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of *Toxocara canis*, *Ancylostoma caninum* and *Uncinaria stenocephala*, adults of *Toxascaris leonina* and *Trichuris vulpis*).

The product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).

4.3 Contraindications

Do not use in puppies under 7 weeks of age.

Do not use in the case of hypersensitivity to the active substances or to any of the excipients.

For cats, the corresponding “Advocate for cat” product, which contains 100 mg/ml imidacloprid and 10 mg/ml moxidectin, must be used.

For ferrets: Do not use Advocate for dogs. Only “Advocate for small cats and ferrets” (0.4 ml) must be used.

4.4 Special warnings

Please refer to section 4.5.

Brief contact of the animal with water on one or two occasions between monthly treatments is unlikely to significantly reduce the efficacy of the product. However, frequent shampooing or immersion of the animal in water after treatment may reduce the efficacy of the product.

Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class.

4.5 Special precautions for use

Special precautions for use in animals

The treatment of animals weighing less than 1 kg should be based on a risk-benefit assessment.

There is limited experience on the use of the product in sick and debilitated animals, thus the product should only be used based on a risk-benefit assessment for these animals.

Care should be taken that the contents of the pipette or the applied dose does not come into contact with the eyes or mouth of the recipient and/or other animals. Do not allow recently treated animals to groom each other. When the product is applied in 3 to 4 separate spots (see section 4.9), specific care should be taken to prevent the animal licking the application sites.

This product contains moxidectin (a macrocyclic lactone), therefore special care should be taken with Collies, Old English Sheepdogs and related breeds or crossbreeds, to correctly administer the product as described under section 4.9; in particular, oral uptake by the recipient and/or other animals in close contact should be prevented.

Advocate should not be allowed to enter surface waters as it has harmful effects on aquatic organisms: moxidectin is highly toxic to aquatic organisms. Dogs should not be allowed to swim in surface waters for 4 days after treatment.

Although the product may be safely administered to dogs infected with adult heartworms, it has no therapeutic effect against adult *Dirofilaria immitis*. It is therefore recommended that all dogs 6 months of age or more, living in areas endemic for heartworm, should be tested for existing adult heartworm infection before being treated with the product.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Avoid contact with skin, eyes or mouth.

Do not eat, drink or smoke during application.

Wash hands thoroughly after use.

After application do not stroke or groom animals until the application site is dry.

In case of accidental spillage onto skin, wash off immediately with soap and water. People with a known hypersensitivity to benzyl alcohol, imidacloprid or moxidectin should administer the product with caution.

In very rare cases the product may cause skin sensitisation or transient skin reactions (for example numbness, irritation or burning/tingling sensation).

In very rare cases the product may cause respiratory irritation in sensitive individuals.

If the product accidentally gets into eyes, they should be thoroughly flushed with water.

If skin or eye symptoms persist, or the product is accidentally swallowed, seek medical attention and show the package insert to the physician.

The solvent in Advocate may stain or damage certain materials including leather, fabrics, plastics and finished surfaces. Allow the application site to dry before permitting contact with such materials.

4.6 Adverse reactions (frequency and seriousness)

Use of the product may result in transient pruritus in dogs. On rare occasions greasy hair, erythema and vomiting can occur. These signs disappear without further treatment. The product may, in rare cases, cause local hypersensitivity reactions. If the animal licks the application site after treatment, neurological signs (most of which are transient) may be observed in very rare cases (see section 4.10).

The product tastes bitter. Salivation may occasionally occur if the animal licks the application site immediately after treatment. This is not a sign of intoxication and disappears within some minutes without treatment. Correct application will minimise licking of the application sites.

The product may in very rare cases cause at the application site a sensation resulting in transient behavioural changes such as lethargy, agitation, and inappetence.

4.7 Use during pregnancy, lactation or lay

The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Laboratory studies with either imidacloprid or moxidectin in rats and rabbits have not produced any evidence of teratogenic, foetotoxic or maternotoxic effects.

Use only according to the risk-benefit assessment by the responsible veterinarian.

4.8 Interaction with other medicinal products and other forms of interaction

During treatment with Advocate no other antiparasitic macrocyclic lactone should be administered.

No interactions between Advocate and routinely used veterinary medicinal products or medical or surgical procedures have been observed.

4.9 Amounts to be administered and administration route

Dosage schedule:

The recommended minimum doses are 10 mg/kg bodyweight imidacloprid and 2.5 mg/kg bodyweight moxidectin, equivalent to 0.1 ml/kg bodyweight Advocate for dogs.

The treatment schedule should be based on the local epidemiological situation.

Weight of dog [kg]	Pipette size to be used	Volume [ml]	Imidacloprid [mg/kg bw]	Moxidectin [mg/kg bw]
≤ 4 kg	Advocate for small dogs	0.4	minimum of 10	minimum of 2.5
> 4–10 kg	Advocate for medium dogs	1.0	10–25	2.5–6.25
> 10–25 kg	Advocate for large dogs	2.5	10–25	2.5–6.25
> 25–40 kg	Advocate for extra-large dogs	4.0	10–16	2.5–4
> 40 kg	the appropriate combination of pipettes			

Flea treatment and prevention

One treatment prevents future flea infestation for 4 weeks. Existing pupae in the environment may emerge for 6 weeks or longer after treatment is initiated, depending upon climatic conditions. Therefore, it may be necessary to combine Advocate treatment with environmental treatments aimed at breaking the flea life cycle in the surroundings. This can result in a more rapid reduction in the household flea population. The product should be administered at monthly intervals when used as part of a treatment strategy for flea allergy dermatitis.

Treatment of biting lice (*Trichodectes canis*)

A single dose should be administered. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment.

Treatment of ear mite infestation (*Otodectes cynotis*)

A single dose of the product should be administered. Loose debris should be gently removed from the external ear canal at each treatment. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment. Do not apply directly to the ear canal.

Treatment of sarcoptic mange (caused by *Sarcoptes scabiei* var. *canis*)

A single dose should be administered twice 4 weeks apart.

Treatment of demodicosis (caused by *Demodex canis*)

The administration of a single dose every 4 weeks for 2 to 4 months is efficacious against *Demodex canis* and leads to a marked improvement of clinical signs particularly in mild to moderate cases. Especially severe cases may require more prolonged and more frequent treatment. To achieve the best possible response in these severe cases, at the discretion of the veterinarian, Advocate can be applied once a week and for a prolonged time. In all cases it is essential that the treatment should be continued until skin scrapings are negative on at least 2 consecutive monthly occasions. Treatment should be stopped in dogs that show no improvement or do not respond in mite count after 2 months treatment. Alternative treatment should be administered. Seek the advice of your veterinarian.

As demodicosis is a multi-factorial disease, where possible, it is advisable to also treat any underlying disease appropriately.

Heartworm prevention

Dogs in areas endemic for heartworm, or those which have travelled to endemic areas, may be infected with adult heartworms. Therefore prior to treatment with Advocate, the advice provided in section 4.5 should be considered.

For prevention of heartworm disease, the product must be applied at regular monthly intervals during the time of the year when mosquitoes (the intermediate hosts which carry and transmit heartworm larvae) are present. The product may be administered throughout the year or at least 1 month before the first expected exposure to mosquitoes. Treatment should continue at regular monthly intervals until

1 month after the last exposure to mosquitoes. To establish a treatment routine, it is recommended that the same day or date be used each month. When replacing another heartworm preventative product in a heartworm prevention programme, the first treatment with Advocate must be given within 1 month of the last dose of the former medication.

In non-endemic areas there should be no risk of dogs having heartworm. Therefore they can be treated without special precautions.

Treatment and prevention of *Angiostrongylus vasorum*

A single dose should be administered. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment.

In endemic areas regular 4 weekly application will prevent angiostrongylosis and patent infection with *Angiostrongylus vasorum*.

Treatment of *Crenosoma vulpis*

A single dose should be administered.

Roundworm, hookworm and whipworm treatment


In areas endemic for heartworm, monthly treatment may significantly reduce the risk of re-infection caused by the respective round-, hook- and whipworms. In areas non-endemic for heartworm, the product can be used as part of a seasonal prevention programme against fleas and gastrointestinal nematodes.

Studies have shown that monthly treatment of dogs will prevent infections caused by *Uncinaria stenocephala*.

Method of administration


For external use only.

Remove one pipette from the package. Then hold the pipette in an upright position, and twist and pull off the cap. Reverse the cap and use it to twist and remove the seal from the pipette, as shown.




For dogs up to 25 kg:

With the dog in a standing position, part the coat between the shoulder blades until the skin is visible. Wherever possible apply to undamaged skin. Place the tip of the pipette on the skin and squeeze the pipette firmly several times to empty its contents directly onto the skin.



For dogs of more than 25 kg:

For easy application the dog should be standing. The entire contents of the pipette should be applied evenly as 3 or 4 spots along the top of the back, from between the shoulders to the base of the tail. At each spot, part the coat until the skin is visible. Wherever possible apply to undamaged skin. Place the tip of the pipette on the skin and gently squeeze the pipette to expel a portion of its contents directly



onto the skin. Do not apply an excessive amount of solution at any one spot, as that could cause some of the product to run down the animal's side.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

Up to 10 times the recommended dose was tolerated in adult dogs with no evidence of adverse effects or undesirable clinical signs. Five times the recommended minimum dose applied at weekly intervals for 17 weeks was investigated in dogs aged over 6 months and tolerated with no evidence of adverse effects or undesirable clinical signs.

The product was administered to puppies at up to 5 times the recommended dose, every 2 weeks for 6 treatments, and there were no serious safety concerns. Transient mydriasis, salivation, vomiting and transient rapid respiration were observed.

After accidental oral ingestion or overdose, neurological signs (most of which are transient) such as ataxia, generalised tremors, ocular signs (dilated pupils, little pupillary reflex, nystagmus), abnormal respiration, salivation and vomiting may occur in very rare cases.

Ivermectin-sensitive Collie dogs tolerated up to 5 times the recommended dose repeated at monthly intervals without any adverse effects, but the safety of application at weekly intervals has not been investigated in ivermectin-sensitive Collie dogs. When 40 % of the unit dose was given orally, severe neurological signs were observed. Oral administration of 10 % of the recommended dose produced no adverse effects.

Dogs infected with adult heartworms tolerated up to 5 times the recommended dose, every 2 weeks for 3 treatments, without any adverse effects.

In case of accidental oral uptake, symptomatic treatment should be administered. There is no known specific antidote. The use of activated charcoal may be beneficial.

4.11 Withdrawal period(s)

Not applicable.

5. PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: therapeutic antiparasitic agent; ATCvet code: QP54AB52.

5.1 Pharmacodynamic properties

Imidacloprid, 1-(6-Chloro-3-pyridylmethyl)-N-nitro-imidazolidin-2-ylideneamine is an ectoparasiticide belonging to the chloronicotinyl group of compounds. Chemically, it is more accurately described as a chloronicotinyl nitroguanidine. Imidacloprid is effective against larval flea stages and adult fleas. Flea larvae in the pet's surroundings are killed after contact with a pet treated with the product. Imidacloprid has a high affinity for the nicotinic acetylcholine receptors in the post-synaptic region of the central nervous system (CNS) of the flea. The ensuing inhibition of

cholinergic transmission in insects results in paralysis and death. Due to the weak nature of the interaction with mammalian nicotinic receptors and the postulated poor penetration through the blood-brain barrier in mammals, it has virtually no effect on the mammalian CNS. Imidacloprid has minimal pharmacological activity in mammals.

Moxidectin, 23-(O-methylloxime)-F28249 alpha is a second-generation macrocyclic lactone of the milbemycin family. It is a parasiticide which is active against many internal and external parasites. Moxidectin is active against larval stages (L3, L4) of *Dirofilaria immitis*. It is also active against gastrointestinal nematodes. Moxidectin interacts with GABA and glutamate-gated chloride channels. This leads to opening of the chloride channels on the postsynaptic junction, the inflow of chloride ions and induction of an irreversible resting state. The result is flaccid paralysis of affected parasites, followed by their death and/or expulsion.

5.2 Pharmacokinetic particulars

After topical administration of the product, imidacloprid is rapidly distributed over the animal's skin within one day of application. It can be found on the body surface throughout the treatment interval. Moxidectin is absorbed through the skin, reaching maximum plasma concentrations approximately 4 to 9 days after treatment in dogs. Following absorption from the skin, moxidectin is distributed systemically and is slowly eliminated from the plasma as manifested by detectable moxidectin concentrations in plasma throughout the treatment interval of one month.

Environmental properties

See sections 4.5. and 6.6.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Benzyl alcohol
Butylhydroxytoluene
Propylene carbonate

6.2 Incompatibilities

None known.

6.3 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.

6.4 Special precautions for storage

Do not store above 30 °C.

6.5 Nature and composition of immediate packaging

Pack sizes 0.4 ml, 1.0 ml, 2.5 ml and 4.0 ml per pipette.
Blister pack containing 1, 2, 3, 4, 6, 9, 12, 21 or 42 unit dose pipettes.

Container material White polypropylene unit dose pipette with screw cap.

Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Advocate should not be allowed to enter surface waters as it has harmful effects on aquatic organisms.

7. MARKETING AUTHORISATION HOLDER

Bayer Animal Health GmbH
D-51368 Leverkusen
Germany

8. MARKETING AUTHORISATION NUMBER(S)

EU/2/03/039/005-012, EU/2/03/039/015-018, EU/2/03/039/023-030, EU/2/03/039/039-054

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

04/2003

10. DATE OF REVISION OF THE TEXT

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency <http://www.ema.europa.eu/>.

PROHIBITION OF SALE, SUPPLY AND/OR USE

Not applicable.

ANNEX II

- A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**
- B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**
- C. STATEMENT OF THE MRLs**

A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer responsible for batch release

KVP Pharma + Veterinär Produkte GmbH
Projensdorfer Str. 324
D-24106 Kiel
Germany

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Veterinary medicinal product subject to prescription.

C. STATEMENT OF THE MRLs

Not applicable.

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE
Advocate spot-on solution for small cats and ferrets
Outer carton, pack size of 1, 2, 3, 4, 6, 9, 12, 21 and 42 pipettes.

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Advocate 40 mg + 4 mg spot-on solution for small cats and ferrets

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

Each 0.4 ml pipette contains:
Active substances: 40 mg imidacloprid, 4 mg moxidectin
Benzyl alcohol
1 mg/ml butylhydroxytoluene (E321: as antioxidant)

3. PHARMACEUTICAL FORM

Spot-on solution

4. PACKAGE SIZE

1 pipette
2 pipettes
3 pipettes
4 pipettes
6 pipettes
9 pipettes
12 pipettes
21 pipettes
42 pipettes

5. TARGET SPECIES

For small cats weighing 4 kg or less and ferrets

6. INDICATION(S)

For cats suffering from, or at risk from, mixed parasitic infections:
For the treatment and prevention of flea infestation (*Ctenocephalides felis*), treatment of ear mite infestation (*Otodectes cynotis*), prevention of heartworm disease (L3 and L4 larvae of *Dirofilaria immitis*) and treatment of infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of *Toxocara cati* and *Ancylostoma tubaeforme*).
The product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).
For ferrets suffering from, or at risk from, mixed parasitic infections:
For the treatment and prevention of flea infestation (*Ctenocephalides felis*) and prevention of heartworm disease (L3 and L4 larvae of *Dirofilaria immitis*).

7. METHOD AND ROUTE(S) OF ADMINISTRATION

For external use only.

Read the package leaflet before use.

8. WITHDRAWAL PERIOD

Not applicable

9. SPECIAL WARNING(S), IF NECESSARY

Read the package leaflet before use.

Do not use in kittens under 9 weeks of age. Consult your veterinarian before using the product on pregnant or lactating cats, or on sick or debilitated cats, or on cats under 1 kg and ferrets under 0.8 kg.

10. EXPIRY DATE

EXP

11. SPECIAL STORAGE CONDITIONS

Do not store above 30 °C

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Any unused product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Advocate should not be allowed to enter surface waters as it has harmful effects on aquatic organisms.

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable

For animal treatment only - to be supplied only on veterinary prescription.

14. THE WORDS “KEEP OUT OF THE REACH AND SIGHT OF CHILDREN”

Keep out of the reach and sight of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Bayer Animal Health GmbH, D-51368 Leverkusen, Germany

16. MARKETING AUTHORISATION NUMBER(S)

EU/2/03/039/001	3 pipettes
EU/2/03/039/002	6 pipettes
EU/2/03/039/013	4 pipettes
EU/2/03/039/019	21 pipettes
EU/2/03/039/020	42 pipettes
EU/2/03/039/031	1 pipette
EU/2/03/039/032	2 pipettes
EU/2/03/039/033	9 pipettes
EU/2/03/039/034	12 pipettes

17. MANUFACTURER'S BATCH NUMBER

Lot

for cats



Flea



Larvae



Hookworm



Roundworm



Heartworm



Otodectes

for ferrets



Flea



Heartworm

PARTICULARS TO APPEAR ON THE OUTER PACKAGE
Advocate spot-on solution for large cats
Outer carton, pack size of 1, 2, 3, 4, 6, 9, 12, 21 and 42 pipettes.

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Advocate 80 mg + 8 mg spot-on solution for large cats

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

Each 0.8 ml pipette contains:
Active substances: 80 mg imidacloprid, 8 mg moxidectin
Benzyl alcohol
1 mg/ml butylhydroxytoluene (E321: as antioxidant)

3. PHARMACEUTICAL FORM

Spot-on solution

4. PACKAGE SIZE

1 pipette
2 pipettes
3 pipettes
4 pipettes
6 pipettes
9 pipettes
12 pipettes
21 pipettes
42 pipettes

5. TARGET SPECIES

For large cats weighing between 4 kg and 8 kg.

6. INDICATION(S)

For cats suffering from, or at risk from, mixed parasitic infections:
For the treatment and prevention of flea infestation (*Ctenocephalides felis*), treatment of ear mite infestation (*Otodectes cynotis*), prevention of heartworm disease (L3 and L4 larvae of *Dirofilaria immitis*) and treatment of infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of *Toxocara cati* and *Ancylostoma tubaeforme*).
The product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).

7. METHOD AND ROUTE(S) OF ADMINISTRATION

For external use only.

Read the package leaflet before use.

8. WITHDRAWAL PERIOD

Not applicable

9. SPECIAL WARNING(S), IF NECESSARY

Read the package leaflet before use.

Do not use in kittens under 9 weeks of age. Consult your veterinarian before using the product on pregnant or lactating cats, or on sick or debilitated cats, or on cats under 1 kg.

10. EXPIRY DATE

EXP

11. SPECIAL STORAGE CONDITIONS

Do not store above 30 °C.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Any unused product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Advocate should not be allowed to enter surface waters as it has harmful effects on aquatic organisms.

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable

For animal treatment only - to be supplied only on veterinary prescription.

14. THE WORDS “KEEP OUT OF THE REACH AND SIGHT OF CHILDREN”

Keep out of the reach and sight of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Bayer Animal Health GmbH, D-51368 Leverkusen, Germany

16. MARKETING AUTHORISATION NUMBER(S)

EU/2/03/039/003	3 pipettes
EU/2/03/039/004	6 pipettes
EU/2/03/039/014	4 pipettes
EU/2/03/039/021	21 pipettes
EU/2/03/039/022	42 pipettes
EU/2/03/039/035	1 pipette
EU/2/03/039/036	2 pipettes
EU/2/03/039/037	9 pipettes
EU/2/03/039/038	12 pipettes

17. MANUFACTURER'S BATCH NUMBER

Lot



Flea



Larvae



Hookworm



Roundworm



Heartworm



Otodectes

PARTICULARS TO APPEAR ON THE OUTER PACKAGE
Advocate spot-on solution for small dogs
Outer carton, pack size of 1, 2, 3, 4, 6, 9, 12, 21 and 42 pipettes.

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Advocate 40 mg + 10 mg spot-on solution for small dogs

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

Each 0.4 ml pipette contains:
Active substances: 40 mg imidacloprid, 10 mg moxidectin.
Benzyl alcohol
1 mg/ml butylhydroxytoluene (E321: as antioxidant)

3. PHARMACEUTICAL FORM

Spot-on solution

4. PACKAGE SIZE

1 pipette
2 pipettes
3 pipettes
4 pipettes
6 pipettes
9 pipettes
12 pipettes
21 pipettes
42 pipettes

5. TARGET SPECIES

For small dogs weighing 4 kg or less.

6. INDICATION(S)

For dogs suffering from, or at risk from, mixed parasitic infections:
For the treatment and prevention of flea infestation (*Ctenocephalides felis*), treatment of biting lice (*Trichodectes canis*), treatment of ear mite infestation (*Otodectes cynotis*), sarcoptic mange (caused by *Sarcoptes scabiei* var. *canis*), demodicosis (caused by *Demodex canis*), prevention of heartworm disease (L3 and L4 larvae of *Dirofilaria immitis*) and angiostrongylosis (L4 larvae and immature adults of *Angiostrongylus vasorum*), treatment of *Angiostrongylus vasorum* and *Crenosoma vulpis* and treatment of infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of *Toxocara canis*, *Ancylostoma caninum* and *Uncinaria stenocephala*, adults of *Toxascaris leonina* and *Trichuris vulpis*).

The product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).

7. METHOD AND ROUTE(S) OF ADMINISTRATION

For external use only.

Read the package leaflet before use.

8. WITHDRAWAL PERIOD

Not applicable

9. SPECIAL WARNING(S), IF NECESSARY

Read the package leaflet before use.

Do not use in puppies under 7 weeks of age. Consult your veterinarian before using the product on pregnant or lactating bitches, or on sick or debilitated dogs, or on dogs under 1 kg.

10. EXPIRY DATE

EXP

11. SPECIAL STORAGE CONDITIONS

Do not store above 30 °C.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Any unused product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Advocate should not be allowed to enter surface waters as it has harmful effects on aquatic organisms.

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable

For animal treatment only - to be supplied only on veterinary prescription.

14. THE WORDS “KEEP OUT OF THE REACH AND SIGHT OF CHILDREN”

Keep out of the reach and sight of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Bayer Animal Health GmbH, D-51368 Leverkusen, Germany

16. MARKETING AUTHORISATION NUMBER(S)

EU/2/03/039/005	3 pipettes
EU/2/03/039/006	6 pipettes
EU/2/03/039/015	4 pipettes
EU/2/03/039/023	21 pipettes
EU/2/03/039/024	42 pipettes
EU/2/03/039/039	1 pipette
EU/2/03/039/040	2 pipettes
EU/2/03/039/041	9 pipettes
EU/2/03/039/042	12 pipettes

17. MANUFACTURER'S BATCH NUMBER

Lot



Flea



Larvae



Whipworm



Hookworm



Roundworm



Angiostrongylus



Crenosoma



Heartworm



Otodectes



Sarcoptes



Demodex



Louse

PARTICULARS TO APPEAR ON THE OUTER PACKAGE**Advocate spot-on solution for medium dogs****Outer carton, pack size of 1, 2, 3, 4, 6, 9, 12, 21 and 42 pipettes.****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Advocate 100 mg + 25 mg spot-on solution for medium dogs

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

Each 1 ml pipette contains:

Active substances: 100 mg imidacloprid, 25 mg moxidectin.

Benzyl alcohol

1 mg/ml butylhydroxytoluene (E321: as antioxidant)

3. PHARMACEUTICAL FORM

Spot-on solution

4. PACKAGE SIZE

1 pipette

2 pipettes

3 pipettes

4 pipettes

6 pipettes

9 pipettes

12 pipettes

21 pipettes

42 pipettes

5. TARGET SPECIES

For medium dogs weighing between 4 kg and 10 kg.

6. INDICATION(S)

For dogs suffering from, or at risk from, mixed parasitic infections:

For the treatment and prevention of flea infestation (*Ctenocephalides felis*), treatment of biting lice (*Trichodectes canis*), treatment of ear mite infestation (*Otodectes cynotis*), sarcoptic mange (caused by *Sarcoptes scabiei* var. *canis*), demodicosis (caused by *Demodex canis*), prevention of heartworm disease (L3 and L4 larvae of *Dirofilaria immitis*) and angiostrongylosis (L4 larvae and immature adults of *Angiostrongylus vasorum*), treatment of *Angiostrongylus vasorum* and *Crenosoma vulpis* and treatment of infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of *Toxocara canis*, *Ancylostoma caninum* and *Uncinaria stenocephala*, adults of *Toxascaris leonina* and *Trichuris vulpis*).

The product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).

7. METHOD AND ROUTE(S) OF ADMINISTRATION

For external use only.

Read the package leaflet before use.

8. WITHDRAWAL PERIOD

Not applicable

9. SPECIAL WARNING(S), IF NECESSARY

Read the package leaflet before use.

Do not use in puppies under 7 weeks of age. Consult your veterinarian before using the product on pregnant or lactating bitches, or on sick or debilitated dogs, or on dogs under 1 kg.

10. EXPIRY DATE

EXP

11. SPECIAL STORAGE CONDITIONS

Do not store above 30 °C.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Any unused product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Advocate should not be allowed to enter surface waters as it has harmful effects on aquatic organisms.

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable

For animal treatment only - to be supplied only on veterinary prescription.

14. THE WORDS “KEEP OUT OF THE REACH AND SIGHT OF CHILDREN”

Keep out of the reach and sight of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER













Bayer Animal Health GmbH, D-51368 Leverkusen, Germany

16. MARKETING AUTHORISATION NUMBER(S)

EU/2/03/039/007	3 pipettes
EU/2/03/039/008	6 pipettes
EU/2/03/039/016	4 pipettes
EU/2/03/039/025	21 pipettes
EU/2/03/039/026	42 pipettes
EU/2/03/039/043	1 pipette
EU/2/03/039/044	2 pipettes
EU/2/03/039/045	9 pipettes
EU/2/03/039/046	12 pipettes

17. MANUFACTURER'S BATCH NUMBER

Lot

-  Flea
-  Larvae
-  Whipworm
-  Hookworm
-  Roundworm
-  Angiostrongylus
-  Crenosoma
-  Heartworm
-  Otodectes
-  Sarcoptes
-  Demodex
-  Louse

PARTICULARS TO APPEAR ON THE OUTER PACKAGE
Advocate spot-on solution for large dogs
Outer carton, pack size of 1, 2, 3, 4, 6, 9, 12, 21 and 42 pipettes.

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Advocate 250 mg + 62.5 mg spot-on solution for large dogs

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

Each 2.5 ml pipette contains:
Active substances: 250 mg imidacloprid, 62.5 mg moxidectin.
Benzyl alcohol
1 mg/ml butylhydroxytoluene (E321: as antioxidant)

3. PHARMACEUTICAL FORM

Spot-on solution

4. PACKAGE SIZE

1 pipette
2 pipettes
3 pipettes
4 pipettes
6 pipettes
9 pipettes
12 pipettes
21 pipettes
42 pipettes

5. TARGET SPECIES

For large dogs weighing between 10 kg and 25 kg.

6. INDICATION(S)

For dogs suffering from, or at risk from, mixed parasitic infections:
For the treatment and prevention of flea infestation (*Ctenocephalides felis*), treatment of biting lice (*Trichodectes canis*), treatment of ear mite infestation (*Otodectes cynotis*), sarcoptic mange (caused by *Sarcoptes scabiei* var. *canis*), demodicosis (caused by *Demodex canis*), prevention of heartworm disease (L3 and L4 larvae of *Dirofilaria immitis*) and angiostrongylosis (L4 larvae and immature adults of *Angiostrongylus vasorum*), treatment of *Angiostrongylus vasorum* and *Crenosoma vulpis* and treatment of infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of *Toxocara canis*, *Ancylostoma caninum* and *Uncinaria stenocephala*, adults of *Toxascaris leonina* and *Trichuris vulpis*).

The product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).

7. METHOD AND ROUTE(S) OF ADMINISTRATION

For external use only.

Read the package leaflet before use.

8. WITHDRAWAL PERIOD

Not applicable

9. SPECIAL WARNING(S), IF NECESSARY

Read the package leaflet before use.

Do not use in puppies under 7 weeks of age. Consult your veterinarian before using the product on pregnant or lactating bitches, or on sick or debilitated dogs, or on dogs under 1 kg.

10. EXPIRY DATE

EXP

11. SPECIAL STORAGE CONDITIONS

Do not store above 30 °C.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Any unused product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Advocate should not be allowed to enter surface waters as it has harmful effects on aquatic organisms.

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable

For animal treatment only - to be supplied only on veterinary prescription.

14. THE WORDS “KEEP OUT OF THE REACH AND SIGHT OF CHILDREN”

Keep out of the reach and sight of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER













Bayer Animal Health GmbH, D-51368 Leverkusen, Germany

16. MARKETING AUTHORISATION NUMBER(S)

EU/2/03/039/009	3 pipettes
EU/2/03/039/010	6 pipettes
EU/2/03/039/017	4 pipettes
EU/2/03/039/027	21 pipettes
EU/2/03/039/028	42 pipettes
EU/2/03/039/047	1 pipette
EU/2/03/039/048	2 pipettes
EU/2/03/039/049	9 pipettes
EU/2/03/039/050	12 pipettes

17. MANUFACTURER'S BATCH NUMBER

Lot

-  Flea
-  Larvae
-  Whipworm
-  Hookworm
-  Roundworm
-  Angiostrongylus
-  Crenosoma
-  Heartworm
-  Otodectes
-  Sarcoptes
-  Demodex
-  Louse

PARTICULARS TO APPEAR ON THE OUTER PACKAGE
Advocate spot-on solution for extra-large dogs
Outer carton, pack size of 1, 2, 3, 4, 6, 9, 12, 21 and 42 pipettes.

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Advocate 400 mg + 100 mg spot-on solution for extra-large dogs

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

Each 4 ml pipette contains:
Active substances: 400 mg imidacloprid, 100 mg moxidectin.
Benzyl alcohol
1 mg/ml butylhydroxytoluene (E321: as antioxidant)

3. PHARMACEUTICAL FORM

Spot-on solution

4. PACKAGE SIZE

1 pipette
2 pipettes
3 pipettes
4 pipettes
6 pipettes
9 pipettes
12 pipettes
21 pipettes
42 pipettes

5. TARGET SPECIES

For extra-large dogs weighing between 25 kg and 40 kg.

6. INDICATION(S)

For dogs suffering from, or at risk from, mixed parasitic infections:
For the treatment and prevention of flea infestation (*Ctenocephalides felis*), treatment of biting lice (*Trichodectes canis*), treatment of ear mite infestation (*Otodectes cynotis*), sarcoptic mange (caused by *Sarcoptes scabiei* var. *canis*), demodicosis (caused by *Demodex canis*), prevention of heartworm disease (L3 and L4 larvae of *Dirofilaria immitis*) and angiostrongylosis (L4 larvae and immature adults of *Angiostrongylus vasorum*), treatment of *Angiostrongylus vasorum* and *Crenosoma vulpis* and treatment of infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of *Toxocara canis*, *Ancylostoma caninum* and *Uncinaria stenocephala*, adults of *Toxascaris leonina* and *Trichuris vulpis*).

The product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).

7. METHOD AND ROUTE(S) OF ADMINISTRATION

For external use only.

Read the package leaflet before use.

8. WITHDRAWAL PERIOD

Not applicable

9. SPECIAL WARNING(S), IF NECESSARY

Read the package leaflet before use.

Do not use in puppies under 7 weeks of age. Consult your veterinarian before using the product on pregnant or lactating bitches, or on sick or debilitated dogs, or on dogs under 1 kg.

10. EXPIRY DATE

EXP

11. SPECIAL STORAGE CONDITIONS

Do not store above 30 °C.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Any unused product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Advocate should not be allowed to enter surface waters as it has harmful effects on aquatic organisms.

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable

For animal treatment only - to be supplied only on veterinary prescription.

14. THE WORDS “KEEP OUT OF THE REACH AND SIGHT OF CHILDREN”

Keep out of the reach and sight of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER


Bayer Animal Health GmbH, D-51368 Leverkusen, Germany

16. MARKETING AUTHORISATION NUMBER(S)

EU/2/03/039/011	3 pipettes
EU/2/03/039/012	6 pipettes
EU/2/03/039/018	4 pipettes
EU/2/03/039/029	21 pipettes
EU/2/03/039/030	42 pipettes
EU/2/03/039/051	1 pipette
EU/2/03/039/052	2 pipettes
EU/2/03/039/053	9 pipettes
EU/2/03/039/054	12 pipettes

17. MANUFACTURER'S BATCH NUMBER

Lot



MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
Advocate for small cats and ferrets
Pipette label

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Advocate



2. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

0.4 ml

3. ROUTE(S) OF ADMINISTRATION

4. BATCH NUMBER

Lot {number}

5. EXPIRY DATE

EXP {month/year}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
Advocate for large cats
Pipette label

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Advocate



2. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

0.8 ml

3. ROUTE(S) OF ADMINISTRATION

4. BATCH NUMBER

Lot {number}

5. EXPIRY DATE

EXP {month/year}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
Advocate for small dogs
Pipette label

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Advocate



2. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

0.4 ml

3. ROUTE(S) OF ADMINISTRATION

4. BATCH NUMBER

Lot {number}

5. EXPIRY DATE

EXP {month/year}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
Advocate for medium dogs
Pipette label

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Advocate



2. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

1 ml

3. ROUTE(S) OF ADMINISTRATION

4. BATCH NUMBER

Lot {number}

5. EXPIRY DATE

EXP {month/year}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
Advocate for large dogs
Pipette label

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Advocate



2. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

2.5 ml

3. ROUTE(S) OF ADMINISTRATION

4. BATCH NUMBER

Lot {number}

5. EXPIRY DATE

EXP {month/year}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
Advocate for extra-large dogs
Pipette label

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Advocate



2. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

4 ml

3. ROUTE(S) OF ADMINISTRATION

4. BATCH NUMBER

Lot {number}

5. EXPIRY DATE

EXP {month/year}

MINIMUM PARTICULARS TO APPEAR ON BLISTERS

Advocate spot-on solution for small cats and ferrets

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Advocate for small cats and ferrets
(≤ 4 kg)

2. CONTENTS BY WEIGHT, BY VOLUME OR NUMBER OF DOSES

0.4 ml

MINIMUM PARTICULARS TO APPEAR ON BLISTERS

Advocate spot-on solution for large cats

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Advocate for large cats

(> 4–8 kg)

2. CONTENTS BY WEIGHT, BY VOLUME OR NUMBER OF DOSES

0.8 ml

MINIMUM PARTICULARS TO APPEAR ON BLISTERS

Advocate spot-on solution for small dogs

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Advocate for small dogs

(≤ 4 kg)

2. CONTENTS BY WEIGHT, BY VOLUME OR NUMBER OF DOSES

0.4 ml

MINIMUM PARTICULARS TO APPEAR ON BLISTERS

Advocate spot-on solution for medium dogs

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Advocate for medium dogs

(> 4–10 kg)

2. CONTENTS BY WEIGHT, BY VOLUME OR NUMBER OF DOSES

1 ml

MINIMUM PARTICULARS TO APPEAR ON BLISTERS

Advocate spot-on solution for large dogs

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Advocate for large dogs

(> 10–25 kg)

2. CONTENTS BY WEIGHT, BY VOLUME OR NUMBER OF DOSES

2.5 ml

MINIMUM PARTICULARS TO APPEAR ON BLISTERS

Advocate spot-on solution for extra-large dogs

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Advocate for extra-large dogs

(> 25–40 kg)

2. CONTENTS BY WEIGHT, BY VOLUME OR NUMBER OF DOSES

4 ml

B. PACKAGE LEAFLET

PACKAGE LEAFLET

Advocate spot-on solution for cats and ferrets

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder:

Bayer Animal Health GmbH
51368 Leverkusen
Germany

Manufacturer for the batch release:

KVP Pharma + Veterinär Produkte GmbH
Projensdorfer Str. 324, 24106 Kiel
Germany

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Advocate 40 mg + 4 mg spot-on solution for small cats and ferrets

Advocate 80 mg + 8 mg spot-on solution for large cats

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Each unit dose pipette delivers:

	Unit Dose	Imidacloprid	Moxidectin
Advocate for small cats (≤ 4 kg) and ferrets	0.4 ml	40 mg	4 mg
Advocate for large cats (> 4 –8 kg)	0.8 ml	80 mg	8 mg

Excipients: Benzyl alcohol, 1 mg/ml butylhydroxytoluene (E 321; as antioxidant)

4. INDICATION(S)

For cats suffering from, or at risk from, mixed parasitic infections:

For the treatment and prevention of flea infestation (*Ctenocephalides felis*), treatment of ear mite infestation (*Otodectes cynotis*), prevention of heartworm disease (L3 and L4 larvae of *Dirofilaria immitis*) and treatment of infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of *Toxocara cati* and *Ancylostoma tubaeforme*).

The product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).

For ferrets suffering from, or at risk from, mixed parasitic infections:

For the treatment and prevention of flea infestation (*Ctenocephalides felis*) and the prevention of heartworm disease (L3 and L4 larvae of *Dirofilaria immitis*).

5. CONTRAINDICATIONS

Do not use in kittens under 9 weeks of age.

Do not use in the case of hypersensitivity to the active substances or to any of the excipients.

The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Laboratory studies with either imidacloprid or moxidectin in rats and rabbits have not produced any evidence of teratogenic, foetotoxic or maternotoxic effects. Use only according to the risk-benefit assessment by the responsible veterinarian.

For ferrets: Do not use Advocate for large cats (0.8 ml) or Advocate for dogs (any size).

For dogs, the corresponding “Advocate for dog” product, which contains 100 mg/ml imidacloprid and 25 mg/ml moxidectin, must be used.

6. ADVERSE REACTIONS

Use of the product may result in transient pruritus in cats. On rare occasions greasy fur, erythema and vomiting can occur. These signs disappear without further treatment.

The product may, in rare cases, cause local hypersensitivity reactions.

In very rare cases (e.g. if the animal licks the application site after treatment or in case of overdose), neurological signs (most of which are transient) such as ataxia, generalised tremors, ocular signs (dilated pupils, little pupillary reflex, nystagmus), abnormal respiration, salivation and vomiting may occur.

The product tastes bitter. Salivation may occasionally occur if the animal licks the application site immediately after treatment. This is not a sign of intoxication and disappears within some minutes without treatment. Correct application will minimise licking of the application site.

The product may in very rare cases cause at the application site a sensation resulting in transient behavioural changes such as lethargy, agitation, and inappetence.

In case of accidental oral uptake, symptomatic treatment should be performed by a veterinary surgeon. There is no known specific antidote. The use of activated charcoal may be beneficial.

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

7. TARGET SPECIES

Cats, ferrets

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

For external use only.

To prevent licking, apply topically to the skin restricting the area of application to the animal's neck at the base of the skull.

Dosage schedule for cats

The recommended minimum doses are 10 mg/kg bodyweight imidacloprid and 1.0 mg/kg bodyweight moxidectin, equivalent to 0.1 ml/kg bodyweight Advocate for cats.

The treatment schedule should be based on the local epidemiological situation.

Weight of cat [kg]	Pipette size to be used	Volume [ml]	Imidacloprid [mg/kg bw]	Moxidectin [mg/kg bw]
≤ 4 kg	Advocate for small cats	0.4	minimum of 10	minimum of 1
> 4–8 kg	Advocate for large cats	0.8	10–20	1–2
> 8 kg	appropriate combination of pipettes			

Flea treatment and prevention

One treatment prevents further flea infestation for 4 weeks. Pre-existing pupae in the environment may continue to emerge for 6 weeks or longer after treatment is initiated depending upon climatic conditions. Therefore, it may be necessary to combine Advocate treatment with treatments aimed at breaking the flea life cycle in the surroundings. This can result in more rapid reductions in the household flea population. The product should be administered at monthly intervals when used as part of a treatment strategy for flea allergy dermatitis.

Treatment of ear mite infestation (*Otodectes cynotis*)

A single dose of the product should be administered. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment. Do not apply directly to the ear canal.

Heartworm prevention

Cats in endemic areas, or those which have travelled to endemic areas, may be infected with adult heartworms. Therefore prior to treatment with Advocate, the advice provided in the section “SPECIAL WARNING(S)” should be considered.

For prevention of heartworm disease, the product must be applied at regular monthly intervals during the time of the year when mosquitoes (the intermediate hosts which carry and transmit heartworm larvae) are present. The product may be administered throughout the year or at least 1 month before the first expected exposure to mosquitoes. The treatment should continue at regular monthly intervals until 1 month after the last exposure to mosquitoes. To establish a treatment routine, it is recommended that the same day or date be used each month. When replacing another heartworm preventative product in a heartworm prevention programme, the first treatment with Advocate must be given within 1 month of the last dose of the former medication.

In non-endemic areas there should be no risk of cats having heartworm. Therefore they can be treated without special considerations.

Roundworm and hookworm treatment

In areas endemic for heartworm, monthly treatment may significantly reduce the risk of re-infection caused by the respective roundworms and hookworms. In areas non-endemic for heartworm, the product can be used as part of a seasonal prevention programme against fleas and gastrointestinal nematodes.

Dosage schedule for ferrets:

One pipette of Advocate spot-on solution for small cats (0.4 ml) should be administered per animal. Do not exceed the recommended dose. The treatment schedule should be based on the local epidemiological situation.

Flea treatment and prevention

One treatment prevents future flea infestation for 3 weeks. Under heavy flea pressure it may be necessary to repeat administration after 2 weeks.

Heartworm prevention


Ferrets in areas endemic for heartworm, or those which have travelled to endemic areas, may be infected with adult heartworms. Therefore prior to treatment with Advocate, the advice provided in the section “SPECIAL WARNING(S)” should be considered.

For prevention of heartworm disease, the product must be applied at regular monthly intervals during the time of the year when mosquitoes (the intermediate hosts which carry and transmit heartworm larvae) are present. The product may be administered throughout the year or at least 1 month before the first expected exposure to mosquitoes. Treatment should continue at regular monthly intervals until 1 month after the last exposure to mosquitoes.


In non-endemic areas there should be no risk of ferrets having heartworm. Therefore they can be treated without special precautions.

9. ADVICE ON CORRECT ADMINISTRATION

Remove one pipette from the package. Then hold the pipette in an upright position, and twist and pull off cap. Reverse the cap and use it to twist and remove the seal from the pipette, as shown.



Part the fur on the animal's neck at the base of the skull until the skin is visible. Place the tip of the pipette on the skin and squeeze the pipette firmly several times to empty its contents directly onto the skin. Application at the base of the skull will minimise the opportunity for the animal to lick the product. Apply only to undamaged skin.



10. WITHDRAWAL PERIOD

Not applicable.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the reach and sight of children.

Do not store above 30 °C.

Do not use after the expiry date stated on the label and carton.

12. SPECIAL WARNING(S)

Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class.

Care should be taken that the contents of the pipette do not come into contact with the eyes or mouth of the recipient and/or other animals. Do not allow recently treated animals to groom each other. Oral uptake by Collies, Old English Sheepdogs and related breeds or crossbreeds should be prevented.

It is recommended that cats and ferrets living in, or travelling to, areas endemic for heartworm are treated monthly with the product to protect them from heartworm disease.

Whilst the accuracy of diagnosis of heartworm infection is limited, it is recommended that attempts be made to check the heartworm status of any cat and ferret aged over 6 months, prior to beginning of prophylactic treatment, as use of the product on cats or ferrets which have adult heartworm may cause serious adverse effects, including death. If adult heartworm infection is diagnosed, the infection should be treated in accordance with current scientific knowledge.

Treatment of cats weighing less than 1 kg and ferrets weighing less than 0.8 kg should be based on a risk-benefit assessment.

The product's efficacy has not been tested in ferrets weighing over 2 kg and therefore the duration of effect might be shorter in these animals.

There is limited experience on the use of the product in sick and debilitated animals, thus the product should only be used based on a risk-benefit assessment for these animals.

Brief contact of the animal with water on one or two occasions between monthly treatments is unlikely to significantly reduce the efficacy of the product. However, frequent shampooing or immersion of the animal in water after treatment may reduce the efficacy of the product.

During treatment with Advocate no other antiparasitic macrocyclic lactone should be administered.

No interactions between Advocate and routinely used veterinary medicinal products or medical or surgical procedures have been observed.

For persons administering Advocate to animals:

Avoid contact with skin, eyes or mouth.

Do not eat, drink or smoke during application.

Wash hands thoroughly after use.

After application do not stroke or groom animals until the application site is dry.

In case of accidental spillage onto skin, wash off immediately with soap and water.

People with a known hypersensitivity to benzyl alcohol, imidacloprid or moxidectin should administer the product with caution.

In very rare cases the product may cause skin sensitisation or transient skin reactions (for example numbness, irritation or burning/tingling sensation).

In very rare case the product may cause respiratory irritation in sensitive individuals.

If the product accidentally gets into eyes, they should be thoroughly flushed with water.

If skin or eye symptoms persist, or the product is accidentally swallowed, seek medical attention and show the package insert to the physician.

The solvent in Advocate may stain or damage certain materials including leather, fabrics, plastics and finished surfaces. Allow the application site to dry before permitting contact with such materials.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Medicines should not be disposed of via wastewater or household waste. Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

15. OTHER INFORMATION

Imidacloprid is effective against larval flea stages and adult fleas. Flea larvae in the pet's surroundings are killed after contact with a pet treated with the product.

Pack sizes: 0.4 ml and 0.8 ml per pipette; blister packs containing 1, 2, 3, 4, 6, 9, 12, 21 or 42 unit dose pipettes.

Not all pack sizes may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

België/Belgique/Belgien

Bayer SA-NV
J.E. Mommaertslaan 14
BE-1831 Diegem (Machelen)
Tel/Tél: +32 2 535 66 54

Luxembourg/Luxemburg

Bayer SA-NV
J.E. Mommaertslaan 14
BE-1831 Diegem (Machelen)
Belgique/Belgien
Tél/Tel: +32 2 535 66 54

Република България

Възраждане-Касис ООД
бул. България 72
BG Ловеч 5500
Тел: + 359 68 604 111

Magyarország

Bayer Hungária Kft.
HU-1123 Budapest
Alkotás u. 50
Tel: +36 1 487 4100

Česká republika

BAYER s.r.o.
Animal Health
Siemensova 2717/4
CZ-155 00 Praha 5
Tel: +420 2 66 10 14 71

Malta

Bayer Animal Health GmbH
DE-51368 Leverkusen
Germany
Tel: +49 2173 38 4012

Danmark

Bayer A/S, Bayer HealthCare
Animal Health Division
Arne Jacobsens Allé 13
DK-2300 København S
Tlf: +45 4523 5000

Deutschland

Bayer Vital GmbH
Geschäftsbereich Tiergesundheit
DE-51368 Leverkusen
Tel: +49 214 301

Eesti

Magnum Veterinaaria AS
Vae 16
EE-76401 Laagri
Tel: +372 650 1920

Ελλάδα

PROVET A.E.
Λεωφ. Ποσειδώνος 77
EL-174 55 Άλιμος, Αττική
Τηλ: +30 210 5575770-3
vet@provet.gr

España

Bayer Hispania, S.L.
División Sanidad Animal
Av. Baix Llobregat, 3-5
ES-08970 Sant Joan Despí (Barcelona)
Tel: +34 93 4956500

France

Bayer Santé
Division Bayer HealthCare Animal Health
13, rue Jean Jaurès
FR-92807 Puteaux cédex
Tél: +33 1 49 06 56 00

Ireland

Bayer Limited, Animal Health Division
The Atrium
Blackthorn Road
IE - Dublin 18
Tel +353 1 2999313

Ísland

Icepharma hf.
Lynghálsi 13
IS-110 Reykjavík
Sími: +354 540 8000

Nederland

Bayer B.V., Animal Health Division
Energieweg 1
NL-3641 RT Mijdrecht
Tel: +31 297 280 666

Norge

Bayer AS
Bayer HealthCare
Animal Health Division
Drammensveien 147 B
NO-0277 Oslo
Tlf: +47 24 11 18 00

Österreich

Bayer Austria GmbH
Geschäftsbereich Tiergesundheit
Herbststraße 6-10
AT-1160 Wien
Tel: +43 1 71146 2850

Polska

Bayer Sp. z o.o. Animal Health
Al. Jerozolimskie 158
PL-02-326 Warszawa
Tel: +48 22 572 35 00

Portugal

Bayer Portugal S.A.
Divisão de Saúde Animal
Rua da Quinta do Pinheiro, 5
PT-2794-003 Carnaxide
Tel: +351 21 4172121

România

S.C. Bayer S.R.L.
Sos. Pipera nr. 42, sector 2
Bucuresti 020112 - RO
Tel: +40 21 529 5900

Slovenija

Bayer d.o.o.
Bravničarjeva 13
SI-1000 Ljubljana
Tel: +386 1 5814 451

Slovenská republika

BAYER s.r.o.
Animal Health
Siemensova 2717/4
CZ-155 00 Praha 5
Česká republika

Tel: +420 2 66 10 14 71

Italia

Bayer S.p.A.
Viale Certosa, 130
IT-20156 Milano
Tel: +39 02 3978 1

Κύπρος

PHARMACARE Ltd.
Μαχαιρά 35
CY-2049 Στρόβολος
Τηλ: +357-22-323060

Latvija

Magnum Veterinaaria AS
Vae 16
EE-76401 Laagri
Tel: +372 650 1920

Lietuva

Magnum Veterinaaria AS
Vae 16
EE-76401 Laagri
Tel.: +372 650 1920

Suomi/Finland

Orion Oyj
ORION PHARMA ELÄINLÄÄKKEET
Tengströminkatu 8, PL/PB 425
FI-20101 Turku/Åbo
Puh/Tel: +358 10 4261

Sverige

Bayer A/S, Bayer HealthCare
Animal Health Division
Arne Jacobsens Allé 13
DK-2300 Köpenhamn S
Danmark
Tel: +46 (0)8-580 223 00

United Kingdom

Bayer plc, Animal Health Division,
Bayer House,
Strawberry Hill,
Newbury,
Berkshire RG14 1JA-UK
Tel: +44 1635 563000

PACKAGE LEAFLET

Advocate spot-on solution for dogs

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder:

Bayer Animal Health GmbH
51368 Leverkusen
Germany

Manufacturer for the batch release:

KVP Pharma + Veterinär Produkte GmbH
Projensdorfer Str. 324, 24106 Kiel
Germany

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Advocate 40 mg + 10 mg spot-on solution for small dogs
Advocate 100 mg + 25 mg spot-on solution for medium dogs
Advocate 250 mg + 62.5 mg spot-on solution for large dogs
Advocate 400 mg + 100 mg spot-on solution for extra-large dogs

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Each unit dose pipette delivers:

	Unit Dose	Imidacloprid	Moxidectin
Advocate for small dogs (≤ 4 kg)	0.4 ml	40 mg	10 mg
Advocate for medium dogs (> 4 –10 kg)	1.0 ml	100 mg	25 mg
Advocate for large dogs (> 10 –25 kg)	2.5 ml	250 mg	62.5 mg
Advocate for extra-large dogs (> 25 –40 kg)	4.0 ml	400 mg	100 mg

Excipients: Benzyl alcohol, 1 mg/ml butylhydroxytoluene (E 321; as antioxidant).

4. INDICATION(S)

For dogs suffering from, or at risk from, mixed parasitic infections:

For the treatment and prevention of flea infestation (*Ctenocephalides felis*), treatment of biting lice (*Trichodectes canis*), treatment of ear mite infestation (*Otodectes cynotis*), sarcoptic mange (caused by *Sarcoptes scabiei* var. *canis*), demodicosis (caused by *Demodex canis*), prevention of heartworm disease (L3 and L4 larvae of *Dirofilaria immitis*) and angiostrongylosis (L4 larvae and immature adults of *Angiostrongylus vasorum*), treatment of *Angiostrongylus vasorum* and *Crenosoma vulpis* and treatment of infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of *Toxocara canis*, *Ancylostoma caninum* and *Uncinaria stenocephala*, adults of *Toxascaris leonina* and *Trichuris vulpis*).

The product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).

5. CONTRAINDICATIONS

Do not use in puppies under 7 weeks of age.

Do not use in the case of hypersensitivity to the active substances or to any of the excipients.

The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Laboratory studies with either imidacloprid or moxidectin in rats and rabbits have not produced any evidence of teratogenic, foetotoxic or maternotoxic effects. Use only according to the risk-benefit assessment by the responsible veterinarian.

For cats, the corresponding “Advocate for cat” product, which contains 100 mg/ml imidacloprid and 10 mg/ml moxidectin, must be used.

For ferrets: Do not use Advocate for dogs. Only “Advocate for small cats and ferrets” (0.4 ml) must be used.

6. ADVERSE REACTIONS

Use of the product may result in transient pruritus in dogs. On rare occasions greasy hair, erythema and vomiting can occur. These signs disappear without further treatment.

The product may, in rare cases, cause local hypersensitivity reactions.

In very rare cases (e.g. if the animal licks the application site after treatment or in case of overdose), neurological signs (most of which are transient) such as ataxia, generalised tremors, ocular signs (dilated pupils, little pupillary reflex, nystagmus), abnormal respiration, salivation and vomiting may occur.

The product tastes bitter. Salivation may occasionally occur if the animal licks the application site immediately after treatment. This is not a sign of intoxication and disappears within some minutes without treatment. Correct application will minimise licking of the application sites.

The product may in very rare cases cause at the application site a sensation resulting in transient behavioural changes such as lethargy, agitation, and inappetence.

In case of accidental oral uptake, symptomatic treatment should be administered by a veterinary surgeon. There is no known specific antidote. The use of activated charcoal may be beneficial.

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

7. TARGET SPECIES

Dogs

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

For external use only.

Apply topically to the skin between the shoulder blades.

Dosage schedule

The recommended minimum doses are 10 mg/kg bodyweight imidacloprid and 2.5 mg/kg bodyweight moxidectin, equivalent to 0.1 ml/kg bodyweight Advocate for dogs.

The treatment schedule should be based on the local epidemiological situation.

Weight of dog [kg]	Pipette size to be used	Volume [ml]	Imidacloprid [mg/kg bw]	Moxidectin [mg/kg bw]
≤ 4 kg	Advocate for small dogs	0.4	minimum of 10	minimum of 2.5
> 4–10 kg	Advocate for medium dogs	1.0	10–25	2.5–6.25
> 10–25 kg	Advocate for large dogs	2.5	10–25	2.5–6.25
> 25–40 kg	Advocate for extra-large dogs	4.0	10–16	2.5–4
> 40 kg	appropriate combination of pipettes			

Flea treatment and prevention

One treatment prevents further flea infestation for 4 weeks. Pre-existing pupae in the environment may continue to emerge for 6 weeks or longer after treatment is initiated depending upon climatic conditions. Therefore, it may be necessary to combine Advocate treatment with treatments aimed at breaking the flea life cycle in the surroundings. This can result in more rapid reductions in the household flea population. The product should be administered at monthly intervals when used as part of a treatment strategy for flea allergy dermatitis.

Treatment of biting lice (*Trichodectes canis*)

A single dose should be administered. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment.

Treatment of ear mite infestation (*Otodectes cynotis*)

A single dose of the product should be administered. Loose debris should be gently removed from the external ear canal at each treatment. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment. Do not apply directly to the ear canal.

Treatment of sarcoptic mange (caused by *Sarcoptes scabiei* var. *canis*)

A single dose should be administered twice 4 weeks apart.

Treatment of demodicosis (caused by *Demodex canis*)

The administration of a single dose every 4 weeks for 2 to 4 months is efficacious against *Demodex canis* and leads to a marked improvement of clinical signs particularly in mild to moderate cases. Especially severe cases may require more prolonged and more frequent treatment. To achieve the best possible response in these severe cases, at the discretion of the veterinarian, Advocate can be applied once a week and for a prolonged time. In all cases it is essential that the treatment should be continued until skin scrapings are negative on at least 2 consecutive monthly occasions. Treatment should be stopped in dogs that show no improvement or do not respond in mite count after 2 months treatment. Alternative treatment should be administered. Seek the advice of your veterinarian.

As demodicosis is a multi-factorial disease, where possible, it is advisable to also treat any underlying disease appropriately.

Heartworm prevention

Dogs in areas endemic for heartworm, or those which have travelled to endemic areas, may be infected with adult heartworms. Therefore before treatment with Advocate, the advice provided in the section “SPECIAL WARNING(S)” should be considered.

For prevention of heartworm disease, the product must be applied at regular monthly intervals during the time of the year when mosquitoes (the intermediate hosts which carry and transmit heartworm larvae) are present. The product may be administered throughout the year or at least 1 month before the first expected exposure to mosquitoes. The treatment should continue at regular monthly intervals until 1 month after the last exposure to mosquitoes. To establish a treatment routine, it is recommended that the same day or date be used each month. When replacing another heartworm preventative product in a heartworm prevention programme, the first treatment with Advocate must be given within 1 month of the last dose of the former medication.

In non-endemic areas there should be no risk of dogs having heartworm. Therefore they can be treated without special precautions.

Treatment and prevention of *Angiostrongylus vasorum*

A single dose should be administered. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment.

In endemic areas regular 4 weekly application will prevent angiostrongylosis and patent infection with *Angiostrongylus vasorum*.

Treatment of *Crenosoma vulpis*

A single dose should be administered.


Roundworm, hookworm and whipworm treatment

In areas endemic for heartworm, monthly treatment may significantly reduce the risk of re-infection caused by the respective roundworm, hookworms and whipworms. In areas non-endemic for heartworm, the product can be used as part of a seasonal prevention programme against fleas and gastrointestinal nematodes.

Studies have shown that monthly treatment of dogs will prevent infections caused by *Uncinaria stenocephala*.


9. ADVICE ON CORRECT ADMINISTRATION

Remove one pipette from the package. Then hold the pipette in an upright position, and twist and pull off the cap. Reverse the cap and use it to twist and remove the seal from the pipette, as shown.




For dogs up to 25 kg:

With the dog in a standing position, part the coat between the shoulder blades until the skin is visible. Wherever possible apply to undamaged skin. Place the tip of the pipette on the skin and squeeze the pipette firmly several times to empty its contents directly onto the skin.



For dogs of more than 25 kg:

For easy application the dog should be standing. The entire contents of the pipette should be applied evenly as 3 or 4 spots along the top of the back, from between the shoulders to the base of the tail. At each spot part the coat until the skin is visible. Wherever possible apply to undamaged skin. Place the tip of the pipette on the skin and gently squeeze the pipette to expel a portion of its contents directly onto the skin. Do not apply an excessive amount of solution at any one spot, as that could cause some of the product to run down the animal's side.



10. WITHDRAWAL PERIOD

Not applicable.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the reach and sight of children.

Do not store above 30 °C.

Do not use after the expiry date stated on the label and carton.

12. SPECIAL WARNING(S)

Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class.

Care should be taken that the contents of the pipette do not come into contact with the eyes or mouth of the recipient and/or other animals. Do not allow recently treated animals to groom each other. When the product is applied in 3 to 4 separate spots, specific care should be taken to prevent the animal licking the application sites.

This product contains moxidectin (a macrocyclic lactone), therefore special care should be taken with Collies, Old English Sheepdogs and related breeds or crossbreeds, to correctly administer the product as described under the section “ADVICE ON CORRECT ADMINISTRATION”; in particular, oral uptake by the recipient and/or other animals in close contact should be prevented.

Although the product may be safely administered to dogs infected with adult heartworms, it has no therapeutic efficacy against adult *Dirofilaria immitis*. It is therefore recommended that all dogs 6 months of age or more, living in areas endemic for heartworm, should be tested for existing adult heartworm infection before being treated with the product.

Treatment of animals weighing less than 1 kg should be based on a risk-benefit assessment.

There is limited experience on the use of the product in sick and debilitated animals, thus the product should only be used based on a risk-benefit assessment for these animals.

Brief contact of the animal with water on one or two occasions between monthly treatments is unlikely to significantly reduce the efficacy of the product. However, frequent shampooing or immersion of the animal in water after treatment may reduce the efficacy of the product.

Advocate should not be allowed to enter surface waters as it has harmful effects on aquatic organisms: moxidectin is highly toxic to aquatic organisms. Dogs should not be allowed to swim in surface waters for 4 days after treatment.

During treatment with Advocate no other antiparasitic macrocyclic lactone should be administered.

No interactions between Advocate and routinely used veterinary medicinal products or medical or surgical procedures have been observed.

For persons administering Advocate to animals:

Avoid contact with skin, eyes or mouth.

Do not eat, drink or smoke during application.

Wash hands thoroughly after use.

After application do not stroke or groom animals until the application site is dry.

In case of accidental spillage onto skin, wash off immediately with soap and water.

People with a known hypersensitivity to benzyl alcohol, imidacloprid or moxidectin should administer the product with caution.

In very rare cases the product may cause skin sensitisation or transient skin reactions (for example numbness, irritation or burning/tingling sensation).

In very rare cases the product may cause respiratory irritation in sensitive individuals.

If the product accidentally gets into eyes, they should be thoroughly flushed with water.

If skin or eye symptoms persist, or the product is accidentally swallowed, seek medical attention and show the package insert to the physician.

The solvent in Advocate may stain or damage certain materials including leather, fabrics, plastics and finished surfaces. Allow the application site to dry before permitting contact with such materials.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Medicines should not be disposed of via wastewater or household waste. Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

15. OTHER INFORMATION

Imidacloprid is effective against larval flea stages and adult fleas. Flea larvae in the pet's surroundings are killed after contact with a pet treated with the product.

Pack sizes: 0.4 ml, 1.0 ml, 2.5 ml and 4.0 ml per pipette; blister packs containing 1, 2, 3, 4, 6, 9, 12, 21 or 42 unit dose pipettes.

Not all pack sizes may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

België/Belgique/Belgien

Bayer SA-NV
J.E. Mommaertslaan 14
BE-1831 Diegem (Machelen)
Tel/Tél: +32 2 535 66 54

Luxembourg/Luxemburg

Bayer SA-NV
J.E. Mommaertslaan 14
BE-1831 Diegem (Machelen)
Belgique/Belgien
Tél/Tel: +32 2 535 66 54

Република България

Възраждане-Касис ООД
бул. България 72
BG Ловеч 5500
Тел: + 359 68 604 111

Magyarország

Bayer Hungária Kft.
HU-1123 Budapest
Alkotás u. 50
Tel: +36 1 487 4100

Česká republika

BAYER s.r.o.
Animal Health
Siemensova 2717/4
CZ-155 00 Praha 5
Tel: +420 2 66 10 14 71

Malta

Bayer Animal Health GmbH
DE-51368 Leverkusen
Germany
Tel: +49 2173 38 4012

Danmark

Bayer A/S, Bayer HealthCare
Animal Health Division
Arne Jacobsens Allé 13
DK-2300 København S
Tlf: +45 4523 5000

Nederland

Bayer B.V., Animal Health Division
Energieweg 1
NL-3641 RT Mijdrecht
Tel: +31 297 280 666

Deutschland

Bayer Vital GmbH
Geschäftsbereich Tiergesundheit
DE-51368 Leverkusen
Tel: +49 214 301

Norge

Bayer AS
Bayer HealthCare
Animal Health Division
Drammensveien 147 B
NO-0277 Oslo
Tlf: +47 24 11 18 00

Eesti

Magnum Veterinaaria AS
Vae 16
EE-76401 Laagri
Tel: +372 650 1920

Österreich

Bayer Austria GmbH
Geschäftsbereich Tiergesundheit
Herbststraße 6-10
AT-1160 Wien
Tel: +43 1 71146 2850

Ελλάδα

PROVET A.E.
Λεωφ. Ποσειδώνος 77
EL-174 55 Άλιμος, Αττική

Polska

Bayer Sp. z o.o. Animal Health
Al. Jerozolimskie 158
PL-02-326 Warszawa

Τηλ: +30 210 5575770-3
vet@provet.gr

España

Bayer Hispania, S.L.
División Sanidad Animal
Av. Baix Llobregat, 3-5
ES-08970 Sant Joan Despí (Barcelona)
Tel: +34 93 4956500

France

Bayer Santé
Division Bayer HealthCare Animal Health
13, rue Jean Jaurès
FR-92807 Puteaux cédex
Tél: +33 1 49 06 56 00

Ireland

Bayer Limited, Animal Health Division
The Atrium
Blackthorn Road
IE - Dublin 18
Tel +353 1 2999313

Ísland

Icepharma hf.
Lynghálsi 13
IS-110 Reykjavík
Sími: +354 540 8000

Italia

Bayer S.p.A.
Viale Certosa, 130
IT-20156 Milano
Tel: +39 02 3978 1

Κύπρος

PHARMACARE Ltd.
Μαχαιρά 35
CY-2049 Στρόβολος
Τηλ: +357-22-323060

Latvija

Magnum Veterinaaria AS
Vae 16
EE-76401 Laagri
Tel: +372 650 1920

Lietuva

Magnum Veterinaaria AS
Vae 16

Tel: +48 22 572 35 00

Portugal

Bayer Portugal S.A.
Divisão de Saúde Animal
Rua da Quinta do Pinheiro, 5
PT-2794-003 Carnaxide
Tel: +351 21 4172121

România

S.C. Bayer S.R.L.
Sos. Pipera nr. 42, sector 2
Bucuresti 020112 - RO
Tel: +40 21 529 5900

Slovenija

Bayer d.o.o.
Bravničarjeva 13
SI-1000 Ljubljana
Tel: +386 1 5814 451

Slovenská republika

BAYER s.r.o.
Animal Health
Siemensova 2717/4
CZ-155 00 Praha 5
Česká republika
Tel: +420 2 66 10 14 71

Suomi/Finland

Orion Oyj
ORION PHARMA ELÄINLÄÄKKEET
Tengströminkatu 8, PL/PB 425
FI-20101 Turku/Åbo
Puh/Tel: +358 10 4261

Sverige

Bayer A/S, Bayer HealthCare
Animal Health Division
Arne Jacobsens Allé 13
DK-2300 Köpenhamn S
Danmark
Tel: +46 (0)8-580 223 00

United Kingdom

Bayer plc, Animal Health Division,
Bayer House,
Strawberry Hill,
Newbury,
Berkshire RG14 1JA-UK
Tel: +44 1635 563000

EE-76401 Laagri
Tel.: +372 650 1920